← 返回

三维成球模型中 CD133 过表达与 TGF-β 补充在卵巢癌细胞系肿瘤发生中的协同作用

英文原题:A synergy of CD133 overexpression and TGF-β supplementation in tumorigenesis of ovarian cancer cell lines in a three-dimensional sphere forming model.

查看英文原题

A synergy of CD133 overexpression and TGF-β supplementation in tumorigenesis of ovarian cancer cell lines in a three-dimensional sphere forming model.

PubMed 2025/08/27(内容时间) Cell Immunol Q3 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

卵巢癌(OC)是致死率很高的妇科恶性肿瘤,主要原因是化疗耐药和肿瘤复发。癌症干细胞(CSC)可能导致化疗耐药,因此已成为新的治疗靶点。本研究旨在建立一种三维(3D)卵巢癌模型,以较好地重现肿瘤微环境(TME)中的干性特征。

在诱导卵巢癌细胞形成球体的过程中,观察到与CSC特性相关的生态位样环境具有CD133阳性细胞。与二维单层培养相比,整合癌症相关成纤维细胞(CAF)的3D卵巢癌多细胞模型更能重现增强的致瘤性和细胞因子介导的侵袭性,并获得化疗耐药性。此外,已建立的整合3D CAF的卵巢癌球体异种移植模型在体内生长时,呈现适当的干性特征和完整的肿瘤发生相关标志物。将CD133基因转导至卵巢癌细胞后,基因本体论(GO)和KEGG通路富集分析显示,细胞因子介导的内皮-间质转化(EMT)可能导致化疗耐药和肿瘤进展;同时观察到PAR1、CXCR4和PD-L1表达升高。此外,我们发现靶向PAR1的工程化嵌合抗原受体(CAR)T细胞对CD133过表达且耐化疗的卵巢癌球体具有显著的体外细胞毒性。

综上,CD133-3D卵巢癌球体能够重现模拟真实晚期卵巢癌状态的TME,可作为有用平台,通过体内外机制验证实验研究卵巢癌化疗、免疫治疗和细胞疗法,进而发现新的治疗策略。

展开英文摘要原文

Ovarian cancer (OC) is a highly lethal gynecological malignancy, mainly due to chemoresistance and tumor recurrence. Cancer stem cells (CSCs) may be responsible for chemoresistance, and CSC has become a new target for treatment. In this study, we aimed to develop a three-dimensional (3D) OC model with well-recapitulated stemness in the tumor microenvironment (TME).

We observed that the niche-like environment associated with CSC properties is characterized by the presence of CD133-positive cells during OC sphere induction. The cancer-associated fibroblast (CAF)-integrated 3D multicellular OC model recapitulates enhanced tumorigenicity and cytokine-mediated invasiveness more than the 2D monolayer culture. Chemoresistance of the 3D OC model is also acquired. In addition, the in vivo growth of an established xenograft model with a 3D CAF-integrated OC sphere exhibits proper stemness features and full cancer-associated markers for tumorigenesis. After transduction of the CD133 gene into OC cells, gene ontology (GO) and KEGG pathway enrichment analyses reveal that cytokine-mediated endothelial mesenchymal transition (EMT) is possibly responsible for chemotherapy resistance and tumor progression, and enhanced PAR1, CXCR4, and PD-L1 expressions are also observed. In addition, we found that engineered chimeric antigen receptor (CAR)-T cells targeting PAR1 demonstrated significant in vitro cytotoxicity toward chemoresistant OC sphere with CD133 overexpression.

Taken together, our results show that a CD133-3D OC sphere recaptures TME that mimics a real late-stage OC condition, and it can act as a useful platform with mechanism-verifying in vitro and in vivo experiments in researching OC chemotherapy, immunotherapy, and cell therapy to discover new therapeutic approaches.

论文信息

作者
Hung HC、Mao TL、Tsui KH、Fan MH、Minhalina AP、Liu CL
第一作者单位
Department of General Surgery, Chang-Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; Chang-Gung University College of Medicine, Taoyuan, Taiwan.Taiwan
通讯作者单位
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Electronic address: chaolien@tmu.edu.tw.Taiwan
文献类型
非美国政府资助研究
期刊
Cellular immunology2025 Nov
原文标识
PubMed 40889488 · DOI 10.1016/j.cellimm.2025.105015